Contak cd study

CLINICAL SUMMARY CONTAK CD - Boston Scientific- US

★ ★ ★ ★ ★

The CONTAK CD Study failed to prospectively demonstrate effectiveness of the CRT portion of the device. The CONTAK CD Study met the Lead and System Effectiveness endpoints as well as the Lead and System Safety endpoints. Subgroup analysis revealed a …

CLINICAL SUMMARY CONTAK CD - Boston Scientific- US

Boston Scientific - Guidant Press Releases

★ ★ ★ ★ ☆

COMPANION Study Stopped Due to Significant Reduction in Combined All-Cause Mortality and All-Cause Hospitalization Cardiac Resynchronization Therapy …

Boston Scientific - Guidant Press Releases

CLINICAL SUMMARY CONTAK RENEWAL - Boston Scientific

★ ★ ☆ ☆ ☆

clinical studies of the VENTAK AV family, upon which the ICD function of CONTAK CD and CONTAK RENEWAL are built, Guidant's ICDs typically have a VF detection time of approximately two seconds. The VF detection time of 2.4 ± 0.5 seconds in ... Finally, during the study CONTAK RENEWAL device counters were found to corre-

CLINICAL SUMMARY CONTAK RENEWAL - Boston Scientific

CONTAK CD slows progression of heart failure - Medscape

★ ★ ★ ★ ☆

Results of Guidant Corporation's CONTAK CD™ trial show the combination pacemaker and implantable defibrillator slowed progression of heart failure by 21%. ... The study was designed to show a 25 ...

CONTAK CD slows progression of heart failure - Medscape

Cardiac resynchronization therapy in patients with right ...

★ ★ ★ ★ ★

The Contak CD study was a prospective randomized, controlled, multicenter, double-blind study that enrolled a total of 581 patients. 4 Entry criteria for participation included patients with NYHA class II to IV, LVEF ≤35%, QRS duration ≥120 ms, and conventional indications for implantable cardioverter-defibrillator placement. Patients in ...

Cardiac resynchronization therapy in patients with right ...

Cardiac resynchronization therapy in patients with right ...

★ ★ ★ ☆ ☆

The Contak CD study was a prospective randomized, controlled, multicenter, double-blind study that enrolled a total of 581 patients.4 Entry criteria for participation in-cluded patients with NYHA class II to IV, LVEF 35%, QRS duration 120 ms, and conventional indications for

Cardiac resynchronization therapy in patients with right ...

contak ® cd - Boston Scientific - slidegur.com

★ ★ ☆ ☆ ☆

contak ® cd - Boston Scientific + Report

contak ® cd - Boston Scientific - slidegur.com

Cardiac resynchronization therapy in patients with right ...

★ ★ ★ ★ ★

Of the 35 patients provided from the Contak CD trial, two were rejected because their ECGs showed LBBB morphology. Of the 43 patients provided from the MIRACLE trial, 15 ECGs were rejected (6 demonstrated intraventricular conduction delay, 7 demonstrated LBBB, 1 was a paced rhythm, and 1 had duplicate information).

Cardiac resynchronization therapy in patients with right ...

European Journal of Heart Failure - Wiley Online Library

★ ★ ★ ★ ★

The CONTAK-CD trial evolved from a study called VENTAK-CHF, the design of which has already been published .The VENTAK-CHF device was designed to provide an implantable defibrillator and cardiac resynchronisation but required a thoracotomy.

European Journal of Heart Failure - Wiley Online Library

Septal to Posterior Wall Motion Delay Fails to Predict ...

★ ★ ★ ☆ ☆

12/20/2005 · Septal to Posterior Wall Motion Delay Fails to Predict Reverse Remodeling or Clinical Improvement in Patients Undergoing Cardiac Resynchronization Therapy Emily Rose, Gregory M. Marcus, Esperanza M. Viloria, Jill Schafer, Teresa De Marco, Leslie A. Saxon, Elyse Foster, for the VENTAK CHF/CONTAK-CD Biventricular Pacing Study Investigators This study was designed to test …

Septal to Posterior Wall Motion Delay Fails to Predict ...

SUMMARY OF SAFETY AND EFFECTIVENESS 1 GENERAL …

★ ★ ★ ★ ★

Summary of Safety and Effectiveness . 5 • Prolonged exposure to fluoroscopic radiation •Renal failure from contrast media used to visualize coronary veins . 10 SUMMARY OF PRE-CLINICAL STUDIES . Guidant's commercially available CONTAK CD system was implanted for the CRT­ D device arm of the COMPANION study. The CONTAK CD system was previously

SUMMARY OF SAFETY AND EFFECTIVENESS 1 GENERAL …

Cardiac resynchronization therapy for the treatment of ...

★ ★ ★ ☆ ☆

10/15/2003 · Finally, the major difference in the studies was the use of mortality, hospitalization, and VT/VF events as the primary end point in the Contak CD study, whereas the MIRACLE and InSync ICD studies selected 6 MW, NYHA class, and QOL as co-primary end points.

Cardiac resynchronization therapy for the treatment of ...

Summary of Safety and Effectiveness Original PMA P010012

★ ★ ★ ★ ☆

Summary of Safety and Effectiveness Original PMA P010012 CONTAK CD ... (hereafter referred to as the CONTAK CD Study) was a prospective, randomized, controlled, multicenter, double -blind study conducted at 47 sites in the United States and enrolled a total of 581 patients. Of these, 57 patients initially underwent a thoracotomy

Summary of Safety and Effectiveness Original PMA P010012

Boston Scientific - Guidant Press Releases

★ ★ ★ ★ ★

Indianapolis, IN - Guidant Corporation (NYSE and PSX: GDT), a worldwide leader in cardiac rhythm management systems, today announced the start of a clinical study to …

Boston Scientific - Guidant Press Releases

Heart Failure Management - What is CRT? | Medtronic

★ ★ ★ ☆ ☆

Boston Scientific — CONTAK CD Study Results. 5 Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial.

Heart Failure Management - What is CRT? | Medtronic

efficacy and safety of cardiac resynchronization therapy ...

★ ★ ★ ★ ☆

2/17/2013 · Later, the CONTAK-CD study, 22 which enrolled 490 patients with NYHA class II–IV, also observed an insignificant difference in clinical conditions, rate of hospitalization, and mortality between CRT-D and ICD therapy groups. However, there were major changes halfway during the process of this trial, therefore, the results of this study should ...

efficacy and safety of cardiac resynchronization therapy ...

Patrick Yong - Academia.edu

★ ★ ★ ☆ ☆

Data were analyzed retrospectively from the VENTAK CHF/CONTAK CD biventricular pacing study. An appropriate safety margin of at least 10 J was verified with at least two successful conversions with 21 J or less. Multivariate logistic regression was performed …

Patrick Yong - Academia.edu

Septal to Posterior Wall Motion Delay Fails to Predict ...

★ ★ ★ ★ ☆

12/20/2005 · Objectives. The aim of this study was to test the hypothesis that a longer septal-to-posterior wall motion delay (SPWMD) would predict greater reverse remodeling and an improved clinical response in heart failure patients randomized to cardiac resynchronization therapy (CRT) in the CONTAK-CD trial.

Septal to Posterior Wall Motion Delay Fails to Predict ...

Mitchell Faddis - Academia.edu

★ ★ ★ ☆ ☆

Data were analyzed retrospectively from the VENTAK CHF/CONTAK CD biventricular pacing study. An appropriate safety margin of at least 10 J was verified with at least two successful conversions with 21 J or less. Multivariate logistic regression was performed …

Mitchell Faddis - Academia.edu

Cardiac resynchronisation may reduce all-cause mortality ...

★ ★ ☆ ☆ ☆

test, is hopelessly reliant on patient motivation. Hospital- All patients enrolled in the CONTAK CD trial [9,10], isation can also easily be biased by knowledge of treatment similar to the InSync ICD, had a clinical indication for ICD. allocation. 0167-5273/$ - see front matter D 2003 Elsevier Ireland Ltd.

Cardiac resynchronisation may reduce all-cause mortality ...

11139906,15505095,18534377 - PubMed Result

★ ★ ★ ★ ★

1: Lozano I, Bocchiardo M, Achtelik M, Gaita F, Trappe HJ, Daoud E, Hummel J, Duby C, Yong P; VENTAK CHF/CONTAK CD Investigators Study Group.. Impact of biventricular pacing on mortality in a randomized crossover study of patients with heart failure and ventricular arrhythmias.

11139906,15505095,18534377 - PubMed Result

Which Patients with Congestive Heart Failure May Benefit ...

★ ★ ★ ★ ★

Without a cut- Hipertrophic cardiomyopathy 6 patients (3%) off for LVDD, including NYHA class II-IV and a Chagas disease 4 patients (2%) QRSd ≥120 ms, up to 35% of the patients ful- Others 13 patients (6.5%) filled the CONTAK CD trials criteria, without indi- cations for …

Which Patients with Congestive Heart Failure May Benefit ...
Aetna-sleep-study-auth-req.html,Af-cdc-study-guides.html,Affirm-heart-study-sheets.html,African-american-lifestyle-study.html,Afrigator-case-study.html